Last updated: 25 January 2024 at 6:06am EST

Katherine Kalin Net Worth



Katherine Kalin biography

Katherine Kalin serves as Director of the Company. Ms. Kalin has more than 25 years of experience as a senior executive in healthcare and professional services, most recently at Celgene Corporation, where she led corporate strategy from 2012 to 2017 and Johnson & Johnson, where she held leadership roles in marketing, sales and new business development from 2002 to 2011. Prior to that, she was a partner in the global healthcare practice of McKinsey & Company from 1990 to 2002. Ms. Kalin currently serves as a non-executive director on the board of Genfit, S.A., a publicly traded French biopharmaceutical company and as a member of the boards of directors of Brown Advisory LLC, an independent investment and strategic advisory firm and Clinical Genomics Technologies, a biotech company dedicated to improving patient outcomes through early detection of colorectal cancer. Ms. Kalin is also a member of the Advisory Board of Stardog, an enterprise data company and PRIMARI Analytics, an artificial intelligence startup. She has a B.A. from Durham University, U.K., and an M.B.A. from Harvard Business School.



Insiders trading at Athersys Inc

Over the last 17 years, insiders at Athersys Inc have traded over $3,715,462 worth of Athersys Inc stock and bought 2,242,389 units worth $3,620,264 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Michael B Sheffery a Jordan Davis. On average, Athersys Inc executives and independent directors trade stock every 43 days with the average trade being worth of $3,231. The most recent stock trade was executed by Daniel A. Camardo on 22 November 2022, trading 100,000 units of ATHX stock currently worth $55,000.



What does Athersys Inc do?

athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.



What does Athersys Inc's logo look like?

Athersys Inc logo

Athersys Inc executives and stock owners

Athersys Inc executives and other stock owners filed with the SEC include: